Mario Mandalà: Can Immunotherapy Be Stopped After Two Years in Melanoma Brain Metastases?

Mario Mandalà, Director of Medical Oncology at S.M. Misericordia Hospital and Associate Professor of Medical Oncology at the University of Perugia, shared a post on LinkedIn:

“Finally, our manuscript on Discontinuation of combo immunotherapy in melanoma patients with brain metastasis. A huge, independent academic effort with clinical implications.

Main messages:

Our study supports discontinuation of COMBO at 24 months in patients with CR and PR. Our study does not support continuing treatment beyond 24 months in patients who have achieved an objective response, since outcomes were similar between patients who continued COMBO and those who discontinued treatment. Strategies to optimize treatment should be pursued in patients who develop irAE after PR, since the long-term control seems to be suboptimal in this subgroup of patients compared with those in CR. Whether a locoregional treatment could be a strategy in this context should be tested in prospective clinical studies.

Thanks to:

Paolo Ascierto, Ryan Sullivan, Maria Chiara Sergi, Georgina Long, Paul Lorigan, Paul Nathan, Heather Shaw, Bart Neyns, Michael Postow, Caroline Robert, Karijn Suijkerbuijk, Hildur Helgadottir, Alice Indini, Reinhard Dummer, DouglasJohnson, IMI – Intergruppo Melanoma Italiano, Eva Muñoz Couselo, Ines Pires Da Silva, Teresa Anaral, Lisa Zimmer, Elisabeth Livingstone, and all my esteemed colleagues and friends !”

Title: Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastases

Authors: Mario Mandalà, Monica Chen, Ryan Sullivan, Maria Chiara Sergi, Michael Postow, Aleigha Lawless, Derek Effiom, Tobias Peres, Paul Lorigan, Patricio Serra-Bellver, Reinhard Dummer, Teresa Amaral, Marie-Lena Rasch, Diana Giannarelli, Maria Grazia Vitale, Hildur Helgadottir, Caroline Robert, Martina Ubaldi, Douglas Johnson, Michele Del Vecchio, Alice Indini, Karijn Suijkerbuijk, Paul Nathan, Thomas Carter, Bart Neyns, Iris Dirven, Ines Pires da Silva, Alexander Maxwell Menzies, Lisa Zimmer, Elisabeth Livingstone, Roberta Depenni, Katharina Kähler, Axel Hauschild, Francesco Spagnolo, Anna Maria Di Giacomo, Ana Arance, Barbara Merelli, Pietro Quaglino, Ernesto Rossi, Marco Tucci, Michele Guida, Eva Muñoz-Couselo, Georgina Long, James Larkin, Paolo Ascierto

Read the article.

Other articles about Melanoma on OncoDaily.